Advanced search
1 file | 126.20 KB

A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application

Author
Organization
Abstract
Developing guidelines on a subject as broad as hypertension is difficult, especially when the guidance relates to hypertension in the chronic kidney disease (CKD) population. The Kidney Disease: Improving Global Outcomes Guideline Development Group has applied a rigorous methodology in reviewing all available evidence, and their recommendations are consistent with the evidence-based approach. As a result, the European Renal Best Practice endorses most of its recommendations. However, the Work Group feels that some additional advice could help clinicians in daily practice: (i) individualization of treatment should be taken into account, especially (cardiovascular) co-morbidities, age, gender and race; (ii) side-effects, such as postural dizziness should be monitored closely, particularly in elderly, diabetics and patients with arterial stiffness; (iii) the importance of salt restriction should not be neglected; (iv) although angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blocker (ARBs) remain a cornerstone in the management of hypertension, and especially cardiovascular protection, in some particular situations such as in advanced CKD and in patients without proteinuria, their role is less well defined; (v) as most CKD patients need more than one antihypertensive drug to achieve blood pressure control, the specific (renal) (dis)advantages of other classes than ACE-I or ARB should be taken into account.
Keywords
European Renal Best Practice, chronic kidney disease, guideline, hypertension, CALCIUM-CHANNEL BLOCKERS, HYPERTENSIVE PATIENTS, HIGH-RISK, TRIAL, THERAPY, HYDROCHLOROTHIAZIDE, NEPHROPATHY, PROGRESSION, INDAPAMIDE, INHIBITOR

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 126.20 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Verbeke, Francis, Elisabeth Lindley, Lucas Van Bortel, Raymond Vanholder, Gérard London, Pierre Cochat, Andrzej Wiecek, Denis Fouque, and Wim Van Biesen. 2014. “A European Renal Best Practice (ERBP) Position Statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: An Endorsement with Some Caveats for Real-life Application.” Nephrology Dialysis Transplantation 29 (3): 490–496.
APA
Verbeke, Francis, Lindley, E., Van Bortel, L., Vanholder, R., London, G., Cochat, P., Wiecek, A., et al. (2014). A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application. NEPHROLOGY DIALYSIS TRANSPLANTATION, 29(3), 490–496.
Vancouver
1.
Verbeke F, Lindley E, Van Bortel L, Vanholder R, London G, Cochat P, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2014;29(3):490–6.
MLA
Verbeke, Francis, Elisabeth Lindley, Lucas Van Bortel, et al. “A European Renal Best Practice (ERBP) Position Statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: An Endorsement with Some Caveats for Real-life Application.” NEPHROLOGY DIALYSIS TRANSPLANTATION 29.3 (2014): 490–496. Print.
@article{5829254,
  abstract     = {Developing guidelines on a subject as broad as hypertension is difficult, especially when the guidance relates to hypertension in the chronic kidney disease (CKD) population. The Kidney Disease: Improving Global Outcomes Guideline Development Group has applied a rigorous methodology in reviewing all available evidence, and their recommendations are consistent with the evidence-based approach. As a result, the European Renal Best Practice endorses most of its recommendations. However, the Work Group feels that some additional advice could help clinicians in daily practice: (i) individualization of treatment should be taken into account, especially (cardiovascular) co-morbidities, age, gender and race; (ii) side-effects, such as postural dizziness should be monitored closely, particularly in elderly, diabetics and patients with arterial stiffness; (iii) the importance of salt restriction should not be neglected; (iv) although angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blocker (ARBs) remain a cornerstone in the management of hypertension, and especially cardiovascular protection, in some particular situations such as in advanced CKD and in patients without proteinuria, their role is less well defined; (v) as most CKD patients need more than one antihypertensive drug to achieve blood pressure control, the specific (renal) (dis)advantages of other classes than ACE-I or ARB should be taken into account.},
  author       = {Verbeke, Francis and Lindley, Elisabeth and Van Bortel, Lucas and Vanholder, Raymond and London, G{\'e}rard and Cochat, Pierre and Wiecek, Andrzej and Fouque, Denis and Van Biesen, Wim},
  issn         = {0931-0509},
  journal      = {NEPHROLOGY DIALYSIS TRANSPLANTATION},
  language     = {eng},
  number       = {3},
  pages        = {490--496},
  title        = {A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application},
  url          = {http://dx.doi.org/10.1093/ndt/gft321},
  volume       = {29},
  year         = {2014},
}

Altmetric
View in Altmetric
Web of Science
Times cited: